Leslie Green, Professor of the Philosophy of Law at Oxford University since 2006, has resigned his Chair effective the end of September. (He will continue with his part-time appointment at Queen's University in Canada.) With the untimely death of John Gardner in 2019,the filling of his prior Chair with a moral philosopher, Timothy Endicott's taking up the Vinerian Chair in English Law (which will focus his energies and supervision in administrative law, rather than jurisprudence), and now Green's departure, the senior ranks in jurisprudence will have been decimated. There still remain many very good younger legal philosophers at Oxford, but since the Professors have primary responsibility for supervision of graduate students, Green's retirement marks the end of an era, that began with H.L.A. Hart's appointment as Professor of Jurisprudence in 1952. Oxford is expected to fill Green's Chair, although I don't know how soon. I can count on one hand (with fingers to spare) the number of appointments that would suffice to sustain Oxford's leadership role in this field. Prospective students will want to watch this carefully.
“[Vaccine] efficacy drops with Delta. That is indisputable,” says Leif Erik Sander, an infectious disease expert at the Charité University Hospital in Berlin. But exactly how much it drops differs across studies. In a report this week analyzing weekly reports on nursing home residents across the United States, researchers found that the messenger RNA (mRNA) vaccines made by Pfizer and Moderna had an efficacy against all infections that went from 75% pre-Delta to 53% after it took over. (The variant accounts for more than 90% of U.S. cases now.)
A large study from the United Kingdom, posted as a preprint yesterday, used the Office for National Statistics COVID-19 Infection Survey, which regularly tests more than 300,000 randomly selected people across the United Kingdom. The study compared the numbers of fully vaccinated and unvaccinated survey participants who tested positive for SARS-CoV-2 during two time periods: December 2020 until 16 May, when the Alpha variant dominated, and 17 May to 1 August, when Delta was dominant. The researchers found that for the two main vaccines in use in the United Kingdom—the Pfizer mRNA vaccine and the adenovirus-based shot developed by the University of Oxford and AstraZeneca—protection against symptomatic infection decreased significantly for the Delta period, to 84% for Pfizer and 71% for AstraZeneca. They also found, consistent with other studies, that compared with breakthrough cases due to the Alpha variant, people with Delta breakthroughs had, on average, much higher viral loads in the nose or throat, suggesting they are more likely to spread the virus to others.
Recent Comments